GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Quality Rank

Tempest Therapeutics (Tempest Therapeutics) Quality Rank


View and export this data going back to 2021. Start your Free Trial

What is Tempest Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Tempest Therapeutics Quality Rank Related Terms

Thank you for viewing the detailed overview of Tempest Therapeutics's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tempest Therapeutics (Tempest Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tempest Therapeutics Inc (NAS:TPST) » Definitions » Quality Rank
Comparable Companies
KRON SYRS LGVN RANI CLNN CRVO TIL CTCX CLSD SLDB OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
3OS:Germany 3OS:Germany
Address
2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Website
https://www.tempesttx.com
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
Executives
Justin Trojanowski officer: Corporate Controller C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Nicholas Maestas officer: VP of Strategy and Finance 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 20005
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Iv, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Iv, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Thomas Woiwode director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Thomas W. Dubensky director, officer: President C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Samuel Whiting officer: Chief Medical Officer C/O TEMPEST THERAPEUTICS, INC., 7000 SHORELINE COURT, SUITE 275, SOUTH SAN FRANCISCO CA 94080
Rock Springs Capital Llc 10 percent owner 650 SOUTH EXETER STREET, SUITE 1070, BALTIMORE MD 21202